Advertisement

Topics

DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM

20:00 EDT 21 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM

NEXT ARTICLE

More From BioPortfolio on "DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM"

Advertisement
Quick Search
Advertisement
Advertisement